Drug Profile


Alternative Names: MPEC; TJN 219; VEN 309

Latest Information Update: 17 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sam Amer & Co
  • Developer Ventrus Biosciences
  • Class Amides; Piperidines; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haemorrhoids

Most Recent Events

  • 11 Jul 2014 Ventrus Biosciences has merged with Assembly Pharmaceuticals to form Assembly Biosciences
  • 25 Jun 2012 Discontinued - Phase-III for Haemorrhoids in USA (Topical)
  • 25 Jun 2012 Final efficacy and adverse events data from a phase III trial for Haemorrhoids released by Ventrus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top